On July 15, Insilico Medicine (03696.HK) rose 6.26% in regular trading, trading at 48.76 HKD/share, with turnover of HKD 241 million.

On the news front, the company announced a multi-faceted strategic alliance with global pharmaceutical manufacturing leader Bora Pharmaceuticals. The partnership aims to integrate Insilico's AI-powered R&D platform with Bora's automation-driven development, manufacturing, and quality execution capabilities to advance innovative drugs from molecular design through commercial delivery. If fully implemented, the potential value of the proposed collaboration is expected to exceed $2.5 billion. The company reminded shareholders and potential investors to exercise caution and not to place undue reliance on the disclosed information.

This deal marks the latest in a series of high-value collaborations for Insilico Medicine, following its $600 million Takeda Pharmaceutical partnership on July 2, a CNS collaboration with CMS yielding up to RMB 1.2 billion in milestone payments on July 13, and a $2.5 billion AI drug discovery pact with SK Biopharmaceuticals in June. The company also recently reported a positive profit alert for H1, projecting revenue of approximately $1.03-1.07 billion and a net profit turnaround of $33.5-39.5 million.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)